• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

New “NeuroCOVID” Classification System Uses MRI to Categorize Patients


Three-stage system can help providers assess patients, as well as guide future treatment and research efforts.

New information about the effects of COVID-19 on the brain continue to emerge with a new study published this week.

In the Journal of Alzheimer’s Disease, Majid Fotuhi, M.D., Ph.D., neurologist and medical director of NeuroGrow Brain Fitness Center in Virginia, revealed a three-stage classification system he called “NeuroCovid” that can be used to categorize patients, as well as guide future research into the neurological effects of the virus.

“We are learning that a significant number of hospitalized COVID-19 patients have various degrees of brain impairment. As a medical community, we need to monitor these patients over time as some of them may develop cognitive decline, attention deficit, brain fog, or Alzheimer’s disease in the future,” said Fotuhi, who is also on staff at Johns Hopkins medicine. “There is a lot we can do to promote brain healing in COVID-19 patients, but first we must understand the nature and severity of their neurological deficits.”

As a first step, he said, patients should get a baseline MRI before leaving the hospital so providers have a comparison for future studies.

To date, more than two dozen case reports have already been published, detailing the stroke, seizures, confusion, dizziness, paralysis, and coma that COVID-19-positive patients have experiences. In one study from Wuhan, China, 45 percent of patient positive for the virus exhibited significant neurological deficits, and another study from France revealed 84 percent of patients in the intensive care unit have neurological abnormalities. Of those patients, 15 percent who leave the ICU have lingering impacts, including poor attention and reduced executive functions.

To help radiologists assess and categorize patients, Fotuhi create this three-stage system:

NeuroCovid Stage 1: Viral damage is limited to epithelial cells of the nose and mouth with main symptoms including transient loss of smell and taste.

NeuroCovid Stage 2: Inflammation, called cytokine storms, floods the body, starting in the lungs and moving to all other body organs through the blood stream. The cytokine storm leads to blood clots that prompt small and large strokes.

NeuroCovid Stage 3: The cytokine storm level is explosive, damaging the blood-brain barrier. This damage allows blood, inflammatory markers, and viral particles to infiltrate the brain. Patients develop seizures, confusion, coma, and encephalopathy.

Fotuhi stressed that many COVID-19-positive patients will not exhibit neurological symptoms initially while others display them before the more commonly expected COVID-19 symptoms of fever, cough, and shortness of breath. It is also important that these patients be followed for several months after they are discharged from the hospital.

“Our experience with previous forms of coronaviruses suggest that in the long-term patients may develop depression, insomnia, Parkinson’s disease, memory loss, or accelerated aging in the brain,” he explained. For those recovering from COVID-19, I recommend regular exercise, eating a heart-healthy diet, reducing stress, and improving sleep; these are critical ways patients can rejuvenate their brain and minimize having poor outcomes in the future.”

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Nina Kottler, MD, MS
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.